Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 10/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25038229 | 1.00 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL22051520 | 1.00 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21739702 | 0.91 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL22052099 | 0.91 | SETD2 (0.33) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21739579 | 0.90 | SETD2 (0.34) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21740283 | 0.90 | SETD2 (0.34) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21739571 | 0.90 | SETD2 (0.34) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21740250 | 0.88 | SETD2 (0.36) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL21739578 | 0.87 | BRD4 (0.32) | SETD2 | |
| SCHEMBL22052822 | 0.84 | SETD2 (0.32) | SETD2NSD2CYP2C8DRD2HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | SETD2 8/4885NSD2 6/4885CYP2C8 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.